Ofatumumab patent expiration date?

What are the details about the patents protecting ofatumumab?

Ofatumumab, also known as Arzerra, is a human monoclonal antibody that targets the CD20 protein found on the surface of B cells, promoting their apoptosis. [1] The drug is used for the treatment of chronic lymphocytic leukemia (CLL) and rheumatoid arthritis.

Can biosimilars enter the market before the patent expires?

According to DrugPatentWatch.com [2], ofatumumab is protected by several patents, the earliest of which is US 9,115,785 B2 granted in 2015. The patent expiry for this particular patent is 2033. However, there are potential ways for biosimilars to enter the market before the patent expiry.

How do the patents and exclusivity impact ofatumumab's availability?

As patents and exclusivity rights expire, the generic or biosimilar versions of the drug become available for the market. Pharmaceutical companies and healthcare providers will then have more options to choose from while treating patients with CLL or rheumatoid arthritis, potentially leading to cost savings and improved access to treatment.

Will patients see a price change once the patent expires?

If a generic or biosimilar version of ofatumumab enters the market before or after the patent expiry, patients may benefit from lower prices. Pharmaceutical companies and manufacturers will need to compete for market share and offer their versions at competitive prices, which may lead to cost savings for patients.

Sources:

[1] DrugPatentWatch.com - Ofatumumab (Arzerra) Patent Information.
[2] DrugPatentWatch.com - Drug Patent News and Patents for generic drugs.